{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:22:00Z","timestamp":1783070520478,"version":"3.54.6"},"reference-count":19,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2007,6,15]],"date-time":"2007-06-15T00:00:00Z","timestamp":1181865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biopharm &amp; Drug Disp"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lovastatin and extended\u2010release (ER) niacin in a fixed dose combination (Advicor<jats:sup>\u00ae<\/jats:sup>) is approved for the treatment of dyslipidemia. Since both drugs are extensively metabolized, this study investigated the bioavailability and pharmacokinetics of their co\u2010administration following single\u2010dose administration. In a 4\u2010way crossover study 40 subjects received: two 1000\/20 Advicor tablets (ADV), two 1000mg niacin ER tablets (NSP), two 20mg lovastatin tablets (Mevacor<jats:sup>\u00ae<\/jats:sup>; MEV), and two niacin ER 1000mg tablets with two lovastatin 20mg tablets (NSP+MEV). Plasma was assayed for niacin, nicotinuric acid (NUA), lovastatin, lovastatin acid and HMGCoA reductase inhibition. Urine was assayed for niacin and its metabolites, NUA, <jats:italic>N<\/jats:italic>\u2010methylnicotinamide and <jats:italic>N<\/jats:italic>\u2010methyl\u20102pyridone\u20105\u2010carboxamide. Least square mean ratios and 90% confidence intervals for <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> and <jats:italic>AUC<\/jats:italic><jats:sub>(0\u2212t)<\/jats:sub> were determined for NSP+MEV versus MEV or NSP, ADV versus MEV or NSP, and ADV versus NSP+MEV. Co\u2010administration of niacin and lovastatin did not significantly influence <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> and <jats:italic>AUC<\/jats:italic><jats:sub>(0\u2212t)<\/jats:sub> of lovastatin, niacin, NUA and total urinary recovery of niacin and metabolites. A 22 to 25% decrease in lovastatin acid <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> was observed while lovastatin acid <jats:italic>AUC<\/jats:italic><jats:sub>(0\u2212t)<\/jats:sub> was not affected. The HMGCoA reductase inhibition <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> and <jats:italic>AUC<\/jats:italic><jats:sub>(0\u2212t)<\/jats:sub> were not affected indicating that the difference in lovastatin acid <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> was not clinically relevant. Copyright \u00a9 2007 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/bdd.555","type":"journal-article","created":{"date-parts":[[2007,8,16]],"date-time":"2007-08-16T02:46:31Z","timestamp":1187232391000},"page":"297-306","source":"Crossref","is-referenced-by-count":11,"title":["The comparative bioavailability of an extended\u2010release niacin and lovastatin fixed dose combination tablet versus extended\u2010release niacin tablet, lovastatin tablet and a combination of extended\u2010release niacin tablet and lovastatin tablet"],"prefix":"10.1002","volume":"28","author":[{"given":"R.","family":"Menon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Tolbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Cefali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,6,18]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"Mevacor prescribing information Merck and Co. November2005."},{"key":"e_1_2_1_3_2","unstructured":"Niaspan prescribing information Kos Pharmaceuticals Inc. 2005."},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)02338-4"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960260304"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(03)00007-9"},{"key":"e_1_2_1_7_2","unstructured":"Advicor prescribing information Kos Pharmaceuticals Inc. 2006."},{"key":"e_1_2_1_8_2","first-page":"33","volume-title":"Metabolic Effects of Nicotinic Acid and its Derivatives","author":"Fumagalli R","year":"1971"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(64)90149-3"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/clinchem\/22.11.1821","article-title":"Metabolic responses of humans to ingestion of nicotinic acid and nicotinamide","volume":"22","author":"Mrochek JE","year":"1976","journal-title":"Clin Chem"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1989.200"},{"key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0021-9258(18)96175-2","article-title":"N\u2010Methylnicotinamide oxidation in a number of mammals","volume":"242","author":"Felsted R","year":"1967","journal-title":"J Biol Chem"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.12.007"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280100329"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1358\/mf.2003.25.6.769652"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.03.137"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1271\/bbb1961.52.2973"},{"key":"e_1_2_1_18_2","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/clinchem\/24.10.1740","article-title":"High\u2010performance liquid\u2010chromatographic determination of free nicotinic acid and its metabolite, nicotinuric acid, in plasma and urine","volume":"24","author":"Hengen N","year":"1978","journal-title":"Clin Chem"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/ajcn\/36.5.926","article-title":"Quantitation of urinary niacin metabolites by reversed\u2010phase liquid chromatography","volume":"36","author":"Carter EG","year":"1982","journal-title":"Am J Clin Nutr"},{"key":"e_1_2_1_20_2","first-page":"22","article-title":"Simultaneous micro\u2010determination of nicotinamide and its major metabolites, N\u2010methyl\u20102\u2010pyridone\u20105\u2010carboxamide and N\u2010methyl\u20104\u2010pyridone\u20103\u2010carboxamide, by high\u2010performance liquid chromatography","volume":"425","author":"Shibata K","year":"1988","journal-title":"J Chromatogr"}],"container-title":["Biopharmaceutics &amp; Drug Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdd.555","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T04:55:41Z","timestamp":1700024141000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdd.555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,18]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1002\/bdd.555"],"URL":"https:\/\/doi.org\/10.1002\/bdd.555","archive":["Portico"],"relation":{},"ISSN":["0142-2782","1099-081X"],"issn-type":[{"value":"0142-2782","type":"print"},{"value":"1099-081X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,18]]}}}